Ozempic
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD
January 17, 2020Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma
Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …
Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes
March 26, 2019Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes
Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …
